RPRX / Royalty Pharma (RPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likel more_horizontal

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial res more_horizontal

Royalty Pharma offers a unique exposure in the pharmaceutical sector thanks to a diversified portfolio and lower operational risk vs. competitors. The more_horizontal

Q2 2023 earnings showcasted robust performance and raised forecast for 2023 non-GAAP adjusted cash receipts. Royalty Pharma enters strategic partnersh more_horizontal

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming inve more_horizontal

Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Royalty Pharma acquires royalties on drugs in the commercial phase and the development phase. Thanks to a milestone payment, this year's cash receipts more_horizontal

NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44t more_horizontal